Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab), HALPRYZA (Rituximab biosimilar), Pemazyre (pemigatinib), olverembatinib, and Cyramza (ramucirumab).
Financial Performance
Despite COVID-19 disruptions in certain cities and regions affecting sales, Innovent has maintained growth momentum across its product portfolio. Tyvyt received new indication approvals for first-line esophageal cancer and first-line gastric cancer in June 2022, following the inclusion of three earlier indications on the National Reimbursement Drug List (NRDL). Other products also continued to show growth.
Product Pipeline
Innovent boasts an innovative product pipeline consisting of 32 prospective drug products covering cancer, metabolic diseases, and autoimmune diseases. Among these, seven products have marketing approvals, three are awaiting regulatory decisions, three are undergoing Phase III or pivotal clinical studies, and 19 are at the pre-clinical stage.-Fineline Info & Tech
